Cargando…

Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer

BACKGROUND: CD47 has high levels of expression in malignant cancer cells, which binds to SIRP-α to release the “don't eat me” signal and prevents mononuclear macrophages from phagocytosing the cells. Resistance to drugs and metastases are potential barriers for prostate cancer endocrine therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Qianqian, Feng, Chunxaing, Chen, Yuchun, Peng, Tianming, Li, Yong, Wu, Kunlin, Pu, Xiaoyong, Chen, Hanzhong, Liu, Jiumin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505079/ https://www.ncbi.nlm.nih.gov/pubmed/37719086 http://dx.doi.org/10.1155/2023/2473075

Ejemplares similares

Comparison of survival in elderly patients treated with uretero-cutaneostomy or ileal conduit after radical cystectomy
por: Huang, Shang, et al.
Publicado: (2021)

Inducing Tumor Suppressive Microenvironments through Genome Edited CD47(−/−) Syngeneic Cell Vaccination
por: Jayaraman Rukmini, Subhadra, et al.
Publicado: (2019)

Targeting CD47 for cancer immunotherapy
por: Jiang, Zhongxing, et al.
Publicado: (2021)

Integrated bioinformatical analysis, machine learning and in vitro experiment-identified m6A subtype, and predictive drug target signatures for diagnosing renal fibrosis
por: Feng, Chunxiang, et al.
Publicado: (2022)

Targeting CD47 as a Novel Immunotherapy for Breast Cancer
por: Chen, Can, et al.
Publicado: (2022)

The expression profiles of CD47 in the tumor microenvironment of salivary gland cancers: a next step in histology-driven immunotherapy
por: Votava, Michal, et al.
Publicado: (2022)

Insights into CD47/SIRPα axis-targeting tumor immunotherapy
por: Zhang, Xuyao, et al.
Publicado: (2018)

Clinical Response to Anti-CD47 Immunotherapy Is Associated with Rapid Reduction of Exhausted Bystander CD4(+) BTLA(+) T Cells in Tumor Microenvironment of Mycosis Fungoides
por: Jiang, Tony T., et al.
Publicado: (2021)

Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma
por: Sun, Jennifer, et al.
Publicado: (2020)

The landscape overview of CD47-based immunotherapy for hematological malignancies
por: Yang, Hua, et al.
Publicado: (2023)

Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies
por: Lu, Quansheng, et al.
Publicado: (2020)

Significance of CD47 and Its Association With Tumor Immune Microenvironment Heterogeneity in Ovarian Cancer
por: Yu, Lan, et al.
Publicado: (2021)

Role of the tumor immune microenvironment in tumor immunotherapy
por: Zhou, Changsheng, et al.
Publicado: (2022)

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
por: Yang, Yan, et al.
Publicado: (2021)

Immunotherapy: Reshape the Tumor Immune Microenvironment
por: LV, Bingzhe, et al.
Publicado: (2022)

CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
por: Wang, Hongfei, et al.
Publicado: (2020)

CD47 Blockade Triggers T cell-mediated Destruction of Immunogenic Tumors
por: Liu, Xiaojuan, et al.
Publicado: (2015)

CD47/SIRPα pathway mediates cancer immune escape and immunotherapy
por: Jia, Xiao, et al.
Publicado: (2021)

Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer
por: Cao, Xu, et al.
Publicado: (2021)

The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy
por: Wo, Yu Jun, et al.
Publicado: (2019)

Therapeutic modulation of the CD47-SIRPα axis in the pediatric tumor microenvironment: working up an appetite
por: Gupta, Ajay, et al.
Publicado: (2020)

Suppressing immunotherapy by organ-specific tumor microenvironments: what is in the brain?
por: Zhang, Chenyu, et al.
Publicado: (2019)

Enhanced tumor immunotherapy by polyfunctional CD19-CAR T cells engineered to secrete anti-CD47 single-chain variable fragment
por: Qiu, Yingqi, et al.
Publicado: (2023)

CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis
por: Gao, Lu, et al.
Publicado: (2016)

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
por: Hu, Jinyang, et al.
Publicado: (2020)

CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
por: Bouwstra, Renée, et al.
Publicado: (2022)

Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer
por: Luo, Xukai, et al.
Publicado: (2023)

Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
por: Zhao, Pengcheng, et al.
Publicado: (2023)

Combining ablative radiotherapy and anti CD47 monoclonal antibody improves infiltration of immune cells in tumor microenvironments
por: Rostami, Elham, et al.
Publicado: (2022)

Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRPα signal
por: Li, Chang, et al.
Publicado: (2022)

Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy
por: Kashyap, Abhishek S., et al.
Publicado: (2020)

Tumor‐Microenvironment‐Responsive Nanomedicine for Enhanced Cancer Immunotherapy
por: Peng, Shaojun, et al.
Publicado: (2021)

Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells
por: Lian, Shu, et al.
Publicado: (2019)

Role of CD47 in Hematological Malignancies
por: Eladl, Entsar, et al.
Publicado: (2020)

CD47‐signal regulatory protein α signaling system and its application to cancer immunotherapy
por: Murata, Yoji, et al.
Publicado: (2018)

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and target for cancer immunotherapy
por: Logtenberg, Meike E. W., et al.
Publicado: (2019)

Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling
por: Shi, Yaoyao, et al.
Publicado: (2020)

JAG1 is correlated to suppressive immune microenvironment and predicts immunotherapy resistance in lung adenocarcinoma
por: He, Jing, et al.
Publicado: (2023)

CD47 antibody protects mice from doxorubicin-induced myocardial damage by suppressing cardiomyocyte apoptosis
por: Hao, Yan, et al.
Publicado: (2022)

Tumor microenvironment and immunotherapy of oral cancer
por: Liu, Chang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_feptukvkma07a3nu5a6fabe09c